#United States #Atlanta #EuroPCR #Nyra Medical #CARLEN System

Nyra Medical's Eye on EuroPCR 2026

Nyra Medical, a pioneering force in the realm of structural heart therapies, is set to showcase its latest advancements during the upcoming EuroPCR meeting. This prestigious event is recognized as a focal point for advancements in cardiovascular care, and Nyra's presentations signify its dedication to clinical excellence and innovation in mitigating heart conditions.

Key Presentations to Anticipate

The involvement of Nyra Medical will feature three pivotal presentations that highlight its latest clinical findings and insights:

1. First-in-Human Experience with the CARLEN System
- Presenter: Dr. Susheel Kodali, Director of the Structural Heart Valve Center at New York-Presbyterian Medical Center.
- Date: May 18, 2026.
- This presentation will delve into the revolutionary CARLEN™ System, specifically its application in treating functional mitral regurgitation.

2. Early Experience from the First-in-Human Study of a Novel Transcatheter Leaflet Augmentation Device
- Presenter: Lori Chmura, CEO of Nyra Medical.
- Date: May 20, 2026.
- Sponsored by Clinical Accelerator, this session focuses on the lessons learned from Nyra's First-in-Human study and the broader implications for heart therapy innovations.

3. Early Human Feasibility Experience with the CARLEN System
- Presenter: Dr. Azeem Latib, Director of Interventional Cardiology and Structural Heart at Montefiore Medical Center.
- Date: May 21, 2026.
- This presentation will explore the feasibility of the CARLEN System in clinical settings, adding to the growing body of evidence supporting its efficacy.

Empowering the Future of Cardiac Care

Lori Chmura, the CEO of Nyra Medical, expressed optimism about the growth momentum accompanying their clinical insights. She stated, "Our participation at EuroPCR reflects the significant momentum we are building across clinical evidence generation, physician partnerships, and strategic growth. Partnering with established medical institutions enhances our journey, facilitating a deeper engagement with healthcare professionals and validating our innovative approaches."

Nyra Medical's intent is clear: to bolster scientific credibility while affirmatively engaging with physicians and healthcare stakeholders. The presentations underscore the company's focused strategy to transition from early-stage clinical trials to larger-scale commercial milestones successfully.

Why EuroPCR Matters

Participation in prominent medical conferences like EuroPCR is crucial for entities such as Nyra Medical. These platforms not only validate the company's clinical trajectory but also establish strategic relationships within the medtech landscape. As the industry evolves, seminars and discussions at these conferences act as catalysts for transformative changes in cardiac care.

About Nyra Medical

Founded with a vision to redefine heart therapies, Nyra Medical operates based on a commitment to innovation and patient-centered solutions. Their flagship product, the CARLEN™ System, aims to revolutionize the treatment of functional mitral regurgitation through a cutting-edge transcatheter design that preserves the valve's natural motion. As they prepare for EuroPCR, Nyra continues to set its sights on improving patients' lives through innovation.

Conclusion

Nyra Medical’s participation at EuroPCR symbolizes its commitment to advancing cardiac therapy through innovative solutions and clinical excellence. As the healthcare community converges for this annual conference, the anticipation of new insights and advancements promises to shape the future of cardiac care.